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Gastric cancer is one of the leading forms of cancer both in regard to its prevalence 
and mortality, ranking fifth and second in the respective categories amongst other 
forms of cancer worldwide. This occurs due to its usually asymptomatic nature at its 
early stages and lack of suiting large-scale methodologies for prognosis and early 
detection for this form of cancer. This leads to late diagnosis, most frequently at a 
metastatic stage, where the applied therapeutical approaches are mostly ineffective. 
Therefore, novel biomarkers for the specialized prognosis and non-invasive diagnosis-
including staging of the disease- of gastric cancer, are required for the personalized 
treatment of the patient. LncRNAs are involved in a huge variety of cellular processes 
as key regulators, and the fact that they have a cell-type and 
developmental/differentiation stage specific expression profile, makes them ideal 
focus points to identify candidate biomarkers for many forms of cancer, including 
gastric. Furthermore, identification and characterization of the effect of non-coding 
variants in regulatory elements of lncRNAs with a deregulated expression profile in 
gastric cancer, further clarifies the utility of the variant for a prognostic test and the 
lncRNA as a target in general. This study focuses on a candidate enhancer of RECUR1, 
an over-expressed lncRNA in gastric cancer, which carries an SNP correlated with 
increased chance of gastric cancer appearance and the survival probability of the 
patient. It was proven that the enhancer indeed has the potential to upregulate the 
expression of RECUR1, albeit further investigation is required. Additionally, the 
appropriate tools for the characterization of the role of the SNP were created and are 
ready to be used in an in cellulo approach.  
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1.1. Gastric Cancer 
1.1.1 Cancer types characterized by extreme variability: Gastric Cancer. 
Gastric cancer is characterized by modest occurrence (5th rank world-wide, 3rd in Asia), 
with twice as many men suffering from the disease relative to women. The average 
age for diagnosis is 60 years old, while there is a rising number of cases reported 
between 40-50 years of age. The most affected countries are China, Korea, and Japan, 
due to genetic predisposition of the population in these areas, as well as due to dietary 
habits and exposure to xenobiotics (Fig 1) [1].  
 
Figure 1: Incident rates of gastric cancer cases worldwide (Both sexes, all ages). Data from WHO/Cancer 
today 2020. 
Most importantly, though, gastric cancer presents the second highest patient 
mortality rates, being surpassed only by lung cancer (Fig 2). This is due to lack of early 
and routine diagnosis of the disease, which usually leads to detection at a later 
metastatic stage [2, 3]. As for the life-expectancy of the patient after the diagnosis, if 
the diagnosis occurs at an early stage, then 95% of the patients may be able to survive 
past the 5 years after diagnosis, while if the diagnosis occurs at a latent stage, then 
the life expectancy drops to less than a year. As for the therapeutic approaches, 
surgical excision of the tumor is considered obsolete in the advanced stages in which 
the diagnosis takes place, and not many sufficient therapeutic approaches have been 
found [4, 5]. Thus, new molecular targets are needed both to ensure early diagnosis 
of the disease, and to create novel treatments for each individual patient [6, 7].  
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Figure 2: Mortality rates of gastric cancer cases worldwide (Both sexes, all ages). Data from 
WHO/Cancer today 2020. 
1.1.2 Phenotypical characteristics of gastric cancer cells  
The histological characteristics of gastric cancer, which include a classification in 
regard to the morphology of the tumor, are well characterized and used for the 
detection of the tumor via gastroscopy. More specifically epithelial cells are most 
commonly transformed leading to appearance of adenocarcinoma (95% of the total 
cases), followed by the less frequent mesenchymal, lymphoproliferative, and 
neuroendocrine types [8]. Further classification of adenocarcinomas is possible, with 
three prominent types [9]:  
1. Intestinal type, in which the morphology of the tumor is similar to that of the 
intestinal tube, in most cases due to existing intestinal metaplasia. It is also 
characterized by cylindrical, gland-like form and thin stroma. This type of 
cancer appears at 54% of the cases, and affects older patients, mostly males. 
2. Diffused type, which is characterized by high EMT, poor cell cohesion and thick 
stroma, while it is also mutation prone. It appears in 32% of adenocarcinoma 
cases, and it is heavily linked with appearance in younger age. 
3. Mixed type, which shares common characteristics with both types. 
1.1.3 Genetic characteristics of gastric cancer cells  
Gastric cancer carries a heavy mutational burden, that either preexists in the genome 
in the form of inherited polymorphisms (SNPs), or by somatic mutations and 
alterations occurring by xenobiotic factors or infectious diseases (such as infection by 
Epstein-Barr virus or Helicobacter pillory).  These lead to CIN (which affects large areas 
of the genome) or to Microsatellite instability (MSI-in which the lesions are restricted 
to a smaller scale), or to genomically stable molecular subtypes. According to The 
Cancer Genome Atlas (TCGA) consortium, gastric cancer cases can be divided into 4 
distinct molecular subtypes based on their genomic signature [10-14]: 
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1. Tumors that correlated with Epstein-Barr virus infection (EBV+) and appear in 
8,8% of the patients. This subtype is characterized by amplification of 9p24.1 
chromosomic area (carries the JAK2 and PD-L1/2 genes), mutations in various 
oncogenes or tumor suppressors such as PI3K, ARID1A and BCOR, while it also 
shows silencing of CDKN2A and rarely mutated p53. Additionally, it shows 
alterations in methylation profile and infiltration of the tumor by T-cells.  
2. Tumors with MSI, that appear in 21,7% of the patients. This subtype is an 
aggressive form that appears in old age, is non-responsive to adjuvant 
chemotherapy and is characterized by hypermutations in various genes, such 
as TP53, PI3KCA, ERBB3 and ARID1A and silencing of MLH1 and various others. 
3. Genomically stable tumors, that appear in 19,7% of the patients. This subtype 
carries multiple mutations in genes relative to cell adhesion such as CDH1 and 
RHOA, fusion of CLDN18 with ARHGAP and enrichment in pathways related 
with angiogenesis. This type is correlated with diffuse histology and 
appearance at a young age. 
4. Tumors with CIN, that take up 49,8% of the total cases. This subtype is mostly 
correlated with intestinal histology metaplasia, and shows extensive 
mutations in TP53, SMAD and APC, as well as activation of the RTK-RAS 
pathway, along with molecules such as EGFR, JAK2 and VEGFA. 
In each of these subtypes, various SNPs are involved with either the tumorigenic 
process or maintenance of gastric cancer cells, depending on their location in the 
genome. These SNPs can have functional impact to a variety of protein coding genes, 
such as the DNA damage repair machinery, xenobiotic metabolism, molecule 
biogenesis processes, or other gene products that are involved in carcinogenesis, such 
as tumor suppressors p53 and CDH1 [15-19]. A special category of SNPs involved in 
tumorigenesis in the case of gastric cancer, includes SNPs in genes that regulate the 
defense against Helicobacter pylori infections [20, 21]. Some SNPs that are positively 
correlated with the appearance of gastric cancer are the intronic SNP rs2976392 (A>G) 
in the PSCA(prostate stem-cell antigen) and intronic SNP rs13361707 (T>C) in 
PRKAA1(which encodes Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) [22, 
23]. 
Chromosomal instability is caused by presence of lengthy copy number variations 
(CNVs) or by chromosomal translocations and is one of the main characteristics of 
gastric cancer. Furthermore, some chromosomal areas are susceptible to these 
alterations in different types of gastric cancer, with alterations in 8q, 17q and 20q 
being prominent in the intestinal subtype of gastric cancer, while in the diffused type 
12q and 13q are the top affected chromosomal areas [24-26]. Due to these, multiple 
reports have shown various loss of heterozygote events (TP53, APC), gene fusions such 
as the one of SLC1A2–CD44 which appears rarely in cancer cells but is a main driver of 
their disorganization and enhancer hijacking as in the case of HER2 (tyrosine kinase 
receptor, part of the MAPK signaling pathway) in 20% of the patients [27-29].  
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The extent of microsatellite instability differs between tumors, classifying them into 
tumors with low and high presence of MSI, depending on the extent of mutation 
occurrence, with alterations in microsatellite length not having a distinct role yet [30]. 
This phenomenon occurs due to deregulation of enzymes that take part in the repair 
mechanisms of the cell, and most prominently in the base-excision repair (BER) 
mechanism due to epigenetic alterations at their promoters. This leads to extended 
presence of mutations in the genome, especially in areas with repeated sequence 
motifs (hence the mutational burden at microsatellites), leading to deregulation of 
many cellular processes [31].  
As with every other type of cancer, the majority of the mutations occur in non-coding 
parts of the genome. Some examples include: 
➢ Introduction of cryptic promoters in areas that in most cases exceeded the 
500bp distance from the TSS, leading to non-canonical mRNA transcripts [32]. 
➢ Mutations at CTCF binding sites linking to CIN, due to the disruption of the 
CTCF Binding Site, leading to altered expression of the neighboring genes (see 
also below). In some cases, such alterations occur in a tissue-specific manner, 
as specific mutations typically predispose only for gastric (and colorectal in 
some extent) cancer onset and rarely for other types [33]. 
➢ Alterations in super-enhancer sequence, epigenetic profile and transcription 
factor occupancy, due to mutations occurring in the area and their enrichment 
in SNPs and copy number alterations [34]. 
➢ Alterations of lncRNA secondary structures, that modify regulatory 
interactions formed by the lncRNAs with RNA-binding proteins and/or miRNAs 
[35]. 
Thus, further combined studies of non-coding variants in regulatory elements and 
ncRNAs has a pivotal role in finding new targets for prognosis, diagnosis, and 
personalized treatment of patients with gastric cancer. 
1.2 The human genome. 
1.2.1 Exploring the human genome 
The human genome has a complex structure, with its functional organization being 
heavily regulated both in terms of structural conformation and DNA sequence 
composition. Within a chromosome, a certain level of compartmentalization can 
occur, with prominent examples being: 1) lamina associated domains (LADs) being 
formed near the nucleolar lamina of the inner nuclear membrane by 
heterochromatinic regions, and 2) topologically associated domains (TADs) whose 
boundaries are restricted by presence of the CCCTC binding factor domains (CTCF 
motifs). Within the TADs, the formation of enhancer-promoter loops is enabled, which 
in turn regulate gene expression (Fig.3)[36-38].   
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Figure 3: Structural organization of the DNA within the nucleus.  
Since the publishing of the first human genome sequences by the Human Genome 
Project, approximately 24,000 protein coding genes have been found (1.5% of the 
genome and ~2% of the transcriptome), while the inclusion of non-coding RNA genes 
(1.5% of the genome and ~98% of the transcriptome) has raised the total number of 
genes to around 40,000, with this number still being debatable since it does not 
account for gene isoforms, that extend beyond 100,000 [39, 40]. Part of the genome 
hosts various regulatory elements such as: 1) enhancers, which are sequences that 
carry transcription factor motifs that induce gene expression 2) silencers, that carry 
motifs for repressive transcription factors and 3) insulator sites that regulate the 
architecture of specific loci, such as CTCF binging sites that determine the limits of 
TADs, (see also below) [41-43]. Each element is characterized by its own set of histone 
modifications, and transcription factor binding motifs. The communication between 
promoters and enhancers is enabled by loop formation within a TAD, the stabilization 
of which can be regulated by lncRNAs that ultimately enable or block gene expression 
(Fig.4) [44, 45].  
The rest of the genome mostly comprises of repetitive DNA sequences like LINEs and 
SINEs, as well as various others whose role is yet to be characterized. At the population 
level, the majority of the DNA sequence is identical to the consensus received by 
HapMap project and lately the Genome Reference Consortium  (GRCh38.p13), yet 
single nucleotide polymorphisms are responsible for 0.1% variation between 
individuals, that raises up to 0.6% percent when we take indels into account [46-49]. 
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Figure 4: The role of DNA regulatory elements and lncRNAs in gene expression. 
1.2.2 The cancer genome. 
Naturally occurring variation, in the form of Single Nucleotide Polymorphisms (SNPs) 
can predispose for tumorigenesis, since a portion of them has been associated with 
tumor initiation, progression, and metastasis [50-53] through genome-wide 
association studies (GWAS). Therefore, SNP alleles indicative of a disease or cancer 
specific subtype serve as risk factors, depending on the strength of the allele that they 
carry. However, due to the presence of linkage disequilibrium in the genome, 
extensive research needs to be conducted in order to distinguish the true positive 
driver alleles, from the neutral and co-segregated passenger mutations [54-56].  
On top of naturally occurring SNPs, the cancer genome gains extensive variability, 
through mutations due to exposure to xenobiotic factors with mutagenic potential, a 
persons’ lifestyle (e.g., smoking) or UV radiation. These mutations may appear in every 
part of the genome, either by causing single nucleotide variations (SNVs), in the form 
of insertions, deletions or duplications, or they may affect wider areas (normally above 
50bp and up to 1Mb), in which we have aneuploidy or duplications of the target 
sequences, thus called copy number variations (CNVs) [57-59]. CNVs may occur either 
in germline cells, thus being correlated with hereditary types of cancer (e.g., familiar 
breast cancer), or they occur in somatic cells, thus being present in various cancer 
types, especially those characterized by Chromosomal INstability (CIN). CNVs can lead 
to carcinogenesis through 3 distinct mechanisms: 1) gene dosage alterations, which 
may affect at least one of the two copies of the gene, 2) gene fusions, and 3) 
alterations occurring on the genes’ regulatory elements, which may in turn affect the 
nature of the in cis- or in trans- interactions formed between the regulatory elements 
and the promoter of the gene-target [60, 61]. In rare occasions, presence of CNV has 
been correlated with alterations in the methylation state of regulatory elements, both 
due to introduction or loss of CpG islets [62]. Such mutations (SNVs and CNVs) have 
already been shown to cause alterations in proteins through non-synonymous amino-
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acid changes that may affect the structural integrity and/or function of the protein in 
various degrees , premature ending of its translation through creation of a stop codon 
in a protein coding gene, altering of the splicing profile through gain or loss of a splicing 
site, gene fusions both in coding and non-coding genes, duplications or deletions of 
genes or their regulatory elements and sequences within them (e.g., promoters, 
enhancers), or even alterations in insulation profile, that may result in ectopic 
chromatin architecture [63-67]. 
The vast majority of the genome and thus the areas in which mutations may occur, 
comprises of genomic areas outside the coding sequences of the protein-coding 
genes. Thus, additional studies are required to shed light to the role of these 
mutations in non-coding regulatory elements and in non-coding RNA genes, the 
downstream function of which is yet to be characterized. More specifically, a possible 
classification of these non-coding mutations according to the genomic area that they 
occur, refer to mutations that occur within [68, 69]:  
➢ Regulatory elements that lie within the transcribed part of a gene (introns, 5’ 
and 3’ untranslated regions-UTRs) which can be found both in protein-coding 
and non-coding transcripts, and  
➢ Regulatory elements that exceed the transcribed area of the gene (promoters, 
enhancers-with the exception of enhancers that lie within intronic sites- 
silencers and insulators). 
Of special interest are mutations that target non-coding RNAs, as their transcript often 
has a regulatory role, thus can be analyzed further as a sub-category of mutations in 
RNA molecules with a regulatory function [70]. 
1.2.2.1 Mutations in transcribed regulatory elements. 
Mutations that target transcribed regulatory elements have various effects in regard 
to the processing, translation (in protein-coding transcripts) and stability of the 
affected transcripts, while in non-coding RNAs it may also affect their ability to execute 
their regulatory function [67, 71]. 
1.2.2.1.1 Mutations in intronic regions 
Intronic areas can be found in many eukaryotic genes. They have many important 
roles, as at the DNA level they may contain enhancers and/or silencers, and at 
transcript level they contain the regulatory elements for splicing and alternate 
splicing. More rarely, introns may also have a role in mRNA exportation from the 
nucleus, nonsense mediated decay (along with the UTRs), or could even be used to 
produce ncRNAs  [72-74]. On some occasions, the intron-mediated enhancement 
(IME) phenomenon may occur, in which the expression levels of the gene that contains 
the intron may be elevated with the effect being present only when the intronic 
sequence is transcribed [75]. Another important function of introns is to protect the 
cells from transcription-mediated genome instability by preventing the formation of 
R-loops, thus blocking the recombination activities that may occur in this state. This 
function is extensively found in highly expressed genes [76]. Many diseases and cancer 
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cases are correlated with splicing alterations, which either lead to exon skipping or 
intron retention, or are caused by mutations that create new splicing sites, thus 
altering a genes’ splicing profile [77]. Occurrence of SNVs in the vicinity of splicing sites 
and exon-intron junctions may result in altered splicing profile, which in some cases 
of tumor suppressor genes such as POT1 (telomere maintenance gene) lead to 
inclusion of exons containing a premature termination codon in blood cancer [78]. 
Further study of this category is needed, as splicing alterations are major players in 
each “hallmark” cancer process that give the tumor a more aggressive identity, 
pinpointing alternative splicing inhibitors as possible therapeutic solutions in cancer 
[79]. 
1.2.2.1.2 Mutations in 5’ and 3’ UTRs  
Both the 5’ and 3’ UTRs have important roles to play in the post-transcriptional 
modifications and translation of the transcript. The 5’ UTR lies upstream of the coding 
sequence and carries the ribosomal binding site, internal ribosome entry sites, as well 
as upstream open reading frames (uORFs). The 3’ UTR lies beyond the stop codon of 
the coding sequence and carries elements for the regulation of translational 
termination, transcript modification and miRNA target sites. Many mutations have 
been found in the UTRs correlating to the general abundance of the transcripts of 
genes related to carcinogenesis, such as Progesterone receptor (PGR) and Erb-B2 
Receptor Tyrosine Kinase 4 (ERBB4) [80]. An example of a SNP within a UTR that is 
linked to cancer predisposition, is the POMC c.*28delT (rs756770132), which lies in 
the 3’UTR of the gene encoding pro-opiomelanocortin. The product of this gene acts 
as a precursor for many signaling molecules, thus linking it to energy metabolism of the 
cancer cells and immune reactions, while alterations of its expression levels are linked 
to increased DNA damage [81]. Recurrent mutations and SNPs in NFKBIZ 3’UTR have 
been correlated with activation of the NF-κΒ signaling pathway in diffuse large B-cell 
lymphoma, due to altered transcriptional regulation and increased transcript levels 
[82]. A graphical abstract of the effects, along with some examples of genes affected 
by mutations in the UTRs can be found on Figure 5 [83]. 
 
Figure 5: Mutations altering the secondary structure of the mRNAs 5’- and 3’-UTRs. These mutations 
may occur in the secondary structures formed to increase the structural stability of the transcript, 
interaction with transcription factors (RBP binding site, IRES) or upstream ORFs in the 5’-UTR, while they 
may affect the poly-adenylation site or miRNA target sites on the 3’UTR. In tumorigenesis, the 
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transcripts of oncogenes tend to have induced stability or alternative ORFs leading to their oncogenic 
effect (gene transcript examples in green coloration), while transcripts of tumor-suppressors tend to 
have shorter stability, translation capacity and increased miRNA targeting (examples in red coloring). 
1.2.2.2 Mutations in non-transcribed regulatory elements.  
Many non-coding variants have been identified within non-transcribed regulatory 
elements and are heavily linked with abnormalities in regulation of transcription. 
These changes may directly affect the function of the specific element at their genomic 
area within a TAD or may occur due to changes that affect the architectural 
organization of a specific locus, thus enabling interactions of elements that would not 
interact under normal conditions. The key interaction that is affected, is the formation 
of promoter-enhancer loops and the functionality of these elements per se [84-86]. 
1.2.2.2.1 Mutations in promoter elements 
Focusing on promoters, and more specifically on the core promoter area, these are 
the main drivers of transcription, as they carry motifs for general transcription factors 
required for the attraction of the RNA-polymerase near the transcriptional start site 
(TSS). In general, promoters can be characterized by the presence of a plethora of 
transcription factor motifs, their (usually) directional activity and ability to activate 
basal levels of transcription [87, 88]. Also, they carry distinct epigenetic signatures for 
active, poised, bivalent and inactive states each characterized by the different 
methylation state of Lysine 4 in histone 3, and the presence of acetylation or 
methylation of Lysine 27 in Histone 3 [89-91]. Promoter mutations in the TERT 
promoter are prominent in various cancer forms (bladder, urothelial, melanoma etc.), 
and especially occurrence of 2 specific SNVs, the -124 C>T and -146 C>T, which lead to 
transcription of the TERT gene (Fig. 6) [92, 93]. The effects of an SNP within a promoter 
comprise of creation of a cryptic promoter/enhancer, alteration of transcription factor 
binding motifs (that may lead to the disruption of the promoter, or creation of a motif 
with stronger binding affinity to the transcription factor) and differential methylation 
of the promoter due to loss or gain of CpG islets [94-98]. Such an example is the case 
of the dominant G allele of the rs11672691 (G/A) SNP, which lies within the promoter 
of the lncRNA PCAT19, turning the promoter into a cryptic enhancer that positively 
regulates the expression of the long isoform of PCAT19, which is linked with aggressive 
form of prostate cancer [99, 100]. Many promoters also carry binding motifs for the 
repressive Yin-Yang 1 (YY1) protein,  and it has been shown that presence of the high-
risk C allele of the SNP rs17079281 (C/T within the promoter of DCBLD1, leads to a 
disruption of the binding motif of YY1, thus removing the repressive effect of the TF 
to the oncogene and initiating lung cancer in European and Asian populations[101]. 
Another prominent example of promoter affecting mutations, is the occurrence of 
either germline or somatic CNVs in the promoter of BRCA1, leading to the destruction 
of the promoter of the tumor-suppressor gene and carcinogenesis based on the two-
hit model[102]. The opposite approach, which refers to activation of oncogenes, 
applies to various subtypes of lung adenocarcinoma, in which destruction of 
methylation sites at promoters has been found  [103]. 
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Figure 6: Mutations in TERT promoter. A) Chart pie of the different alterations occurring in the TERT 
promoter during its reactivation in cancer. B) Localization of the -124 C>T and -146 C>T mutations of 
the TERT promoter. C) The 2 mutations promote looping of the promoter with a putative enhancer 
region, leading to reactivation of TERT expression. 
1.2.2.2.2 Mutations in enhancer elements 
Genomic areas that carry binding motifs for activating transcription factors and 
interact with promoters usually within a TAD in the 3D space, are characterized as 
putative enhancers [104-107]. Enhancers are also characterized by developmental 
stage and cell-type specific manner of activation, as not all enhancers are active in a 
specific cell-type in each given time of its development, while some enhancers may 
also act as silencers in some cell types due to the duality through which their 
associated transcription factors act (prime example are the enhancers that bind CDX2, 
which frequently have  repressive effects in the cancerous intestine and activating role 
in gastric cancer) [108, 109]. On an epigenetic level, several histone modifications that 
decorate enhancers, mark them as active, poised, and inactive, depending on the 
presence of H3K4me1, H3K4me2, H3K4me3, H3K27ac and H3K27me3 histone 
modifications (Fig.7) [110]. 
C 
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Figure 7: Enhancer activity based on their histone modification signature. Active enhancers are 
characterized by the presence of H3K4me2 and H3K27ac, while poised enhancers show increased levels 
of H3K4me1 and H3K27me3. Finally, repressed enhancers show extended presence of the H3K4me3 
histone modification. 
Since the enhancers may act independently of their location in relation to the 
promoter they activate, they can be found anywhere within the corresponding TAD, 
while loop formation, ensures close proximity with the target promoter in the 3D 
space [111].  Enhancers can be also characterized by expression of enhancer RNAS 
(eRNAs), which are short, bidirectional transcripts produced at the site of the 
enhancer, either prior to or following the formation of the enhancer-promoter loop, 
depending on the case, with a suggested role for these transcripts being the 
stabilization of this loop along the formation of the mediator complex, in order to 
proceed to the expression of the target gene [112-114]. When multiple enhancers that 
show high enrichment in transcription factor motifs and extended transcription of 
eRNAs at their genomic sites, aggregate on a genomic area, they are deemed as Super-
enhancers. Super-enhancers span wide genomic areas and can regulate the 
expression levels of pluripotency genes in stem cells, as well as other genes in cell-
type specific manner. A summary of the above can be seen in Figure 8 [115, 116]. 
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Figure 8: Enhancer activity in promoting gene expression. Bothe enhancers and super-enhancers may 
form loops with promoters, each of them occupied with the transcription factors able to regulate the 
gene expression. Stabilization of the enhancer-promoter loop is performed by the eRNAs, which are bi-
directionally transcribed at the enhancer elements by RNA-polII. The enhancer may be either in an active 
or poised state, which is regulated by the histone modification signatures around the enhancer.  
Ectopic activity of enhancers and super-enhancers is heavily linked with disease onset 
and progression, due to their inherent role in upregulating a gene’s expression levels. 
Thus, deregulation of these elements, either due to variants that alter transcription 
factor binding affinity, variants that disrupt or lead to the creation of (super)enhancers 
or variants that alter TAD boundaries, giving these elements new promoters to 
interact with, is crucial for tumorigenesis (Fig.9) [117].  
Such an example is the SNP rs11672691 in the promoter of lncRNA PCAT19, which is 
found within the binding motif of the HOX2A TF in an enhancer regulating the 
expression of the lncRNA. The G allele of this SNP increases binding affinity of the 
transcription factor, leading to stabilization of the enhancer-promoter loop and 
increased expression levels of the oncogenic lncRNA [118]. Another example of an 
enhancer that carries an SNP that alters the binding capacity of TFs, is an enhancer 
regulating MYC and the lncRNA PVT1. The allele AC of the SNP rs35252396 variant 
(AC>CG), is positively correlated with increased binding of the hypoxia inducible 
factors (HIFs) to this enhancer, thus promoting survival of the cancer cells, with a 
prominent role in renal adenocarcinoma [119]. Moreover, CNVs that cause creation 
of  super-enhancers are considered hallmarks of cancer, with a prominent regulatory 
effect in various driver oncogenes in many different types of cancer [34].  
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Figure 9: Mutations affecting the enhancers’ regulatory wiring to target-promoters. Enhancer deletion 
due to presence of CNVs(a), or due to a point mutation or SNP that disrupts a binding motif of a TF 
crucial for its function(b). An SNP or point mutation may also create a binding motif with stronger 
affinity for a TF, or a CNV might duplicate part of the enhancer (c), or the entire enhancer (d) if they are 
found within the enhancer, or they can create a de novo enhancer (e). Similarly, they can create a new 
promoter for the enhancer to activate (f) or delete an already existing one, thus the enhancer might 
activate the next closest promoter within a TAD (g). Finally, when the TAD boundaries are compromised, 
then the enhancer may activate a gene promoter which lies at a different TAD, that they would never 
interact under normal circumstances, with the phenomenon being described as enhancer hijacking(h). 
1.2.2.2.3 Mutations in silencer and insulator elements 
Studies of silencer and insulator elements are relatively new, with even fewer data 
available with regards to the role of specific variants that lie within them. Both 
elements have a significant fine-tuning role in a gene’s regulation of expression [120]. 
Silencers carry binding motifs for repressive transcription factors, or histone 
methyltransferases, that catalyze the repressive trimethylation of lysine 72 of histone 
3 in the promoters of the gene targets [121]. Some silencers have the ability to bind 
transcription factors both in their unmethylated and lowly methylated forms, such as 
FRA1, BACH2 and EBF1 transcription factors [122-124]. An example of a SNP that 
destroys a binding motif for a repressive TF can be the SNP rs249473, which lies within 
a silencer element, with the A high risk allele disrupting the binding motif for YY1. 
Under normal circumstances, YY1 would act in this case by downregulating the 
expression of AKT1, which is part of the PI3K/AKT/mTOR pathway, a pathway whose 
deregulation has a prominent role in various types of cancer, such endometrial and 
thyroid cancers [125]. As for the insulator elements, they are rich in binding motifs for 
CTCF, and their main function is to create interchromosomal barriers that either 
insulate different TADs, or act as a limit for heterochromatic regions[126]. Loss of 
insulator elements mostly due to CNVs has been described in various CIN cancers with 
these elements acting as the main drivers for the enhancer hijacking phenomena 
[127]. 
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1.2.2.3 Mutations in non-coding RNAs.  
Non-coding RNAs (ncRNAs) have a plethora of regulatory roles, and are directly 
involved in many cellular processes, such as regulation of the cells’ growth rate and 
division, differentiation and apoptosis. Also, many ncRNAs show cell- and stage- 
specific activation pattern, further signifying regulatory fine tuning as their primary 
mode of action. Due to this fact, their deregulation has a prominent role in cancer 
onset, development, rate of differentiation and tumor metastasis [128-132].  
Depending on their length, ncRNAs can be distinguished into short non-coding RNAs 
such as miRNAs, with a processed transcript length that is less than 200nt,  and into 
long non-coding RNAs (lncRNAs), the transcript lengths of which exceed 200nt [133]. 
Key regulators for the different stages of the disease fall in both categories, so their 
study can be beneficial both in finding new prognostic and diagnostic markers, but 
also possible therapeutical targets, with higher specificity than the existing ones, 
which mainly refer to mRNAs  [134, 135]. 
1.2.2.3.1 Role of miRNAs and their mutations. 
miRNAs are small ncRNAs that are transcribed by MIR genes, and their main function 
is to target mRNA transcripts, inhibiting their translation and/or leading them to 
degradation [136, 137]. Depending on their effect in cancer, miRNAs can be classified 
as oncogenic miRNAs (oncomiRs) and tumor-suppressive miRNAs(tsmiRs), thus their 
expression profile can be useful for monitoring the disease state. Their value as 
diagnostic markers is also highlighted by their ability to maintain their integrity in 
various biological samples, with most prominent being blood serum [138, 139]. 
OncomiRs have increased expression levels in cancer cells and are linked with 
increased ability of the cancer cells to survive, to execute the epithelial to 
mesenchymal transition (EMT), and to increase the metastatic ability of the cells, 
through the degradation of tumor suppressor genes [140]. On the other hand, the 
transcriptional levels of tumor suppressing miRs are reduced in cancer cells, as their 
function is to target oncogenic mRNAs, thus mutations that lead to downregulation or 
loss of these transcripts and their subsequent genomic loci provide an advantage for 
the survival of the cancer cell [141]. A single mature miRNA product can have multiple 
targets, thus mutations in miRNAs and their precursor molecules may affect the 
expression of multiple genes at once [142]. Examples of a variant within a miRNA 
precursor that affects its levels is the SNPs  rs11614913 in miR-196a-2 (TT>CC), which 
leads to ineffective cleavage of the pre-miRNA in lung, breast, and gastric cancer 
(Fig.10)  [143]. Additional examples are the rs7372209(CC>CT>TT)  in 5’ region of pri-
miR62a-1 (putative targets include E2F7, SMAD1 and EZH2) and rs1834306(A>G)  in 5’ 
region of pri-miR-100 (HOXA as a putative target), seemingly affecting their 
maturation processing and being correlated with increased drug resistance in 
metastatic colon cancer [144]. In some cancer types oncomiR loci can be duplicated 
due to CNVs, leading to increased expression levels. Such examples are the high 
expression levels of miR-296-5p, miR-3928-3p and miR-324-3p, which are correlated 
with poor prognosis in patients with Squamous cell lung carcinoma, as they target 
FAM46C leading to increased expression of MYC [145].  
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Figure 10:  SNP effect on pre-miRNA processing-case study of the rs11614913 SNP, which is part of the 
miR-196α-2 pre-miRNA. The wild-type CC allele is correlated with increased efficiency of the pre-miRNA 
processing, while the TT allele leads to reduced levels of the mature miRNA, correlated with increased 
risk for susceptibility for various forms of cancer. 
1.2.2.3.2 Role of lncRNAs and their mutations. 
lncRNAs are transcripts that undergo capping and polyadenylation similarly to mRNAs 
[146]. They can be transcribed from a plethora of genomic areas and can act either in 
cis or in trans with respect to their target gene. They can be transcribed by intergenic 
or intronic areas, or by an alternative promoter site in parallel or anti-parallel of a 
protein-coding gene, while in some rare occasions circular lncRNAs (circRNAs) may 
occur by an exonic or intronic part of a gene [147]. One of the peculiarities of the 
lncRNAs’ expression profile is that they show a high degree of specialization according 
to the cell-type and/or developmental/differentiation stage. They have many different 
functional roles within a cell, which can be further distinguished to their roles in the 
cytoplasm, and their roles within the nucleus [148, 149]. More specifically, in the 
nucleus:  
1. They can interfere with chromatin writers that establish the epigenetic profile 
both in chromatin and DNA level, either by affecting positively or negatively 
their activity, or by targeting or blocking their localization to specific loci. These 
responses are specific for each lncRNA-protein interaction, as each lncRNA 
may alter the properties of its associating proteins in a different manner [150, 
151]. 
2. They may interact with TFs and the RNA polymerase either by enhancing their 
affinity to interact with their binding sites, or by blocking their transcriptional 
role, as well as by stabilizing the promoter-enhancer loops, thus playing a key 
role in the regulation of the levels of transcription of a target gene [132, 152]. 
3. They promote intrachromosomal and interchromosomal interactions [153, 
154]. 
4. They are responsible for the formation and action of the splicing machinery 
[155, 156]. 
On the other hand, cytoplasmic lncRNAs: 
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1. may act as miRNA sponges that have sequences that mimic those recognized 
by the miRNA in their mRNA targets. As a result, the miRNAs target the lncRNAs 
instead of the actual mRNA, thus enabling the latter to further be translated. 
In cancer, lncRNAs whose sites mimic those of oncogenes, are upregulated, 
thus the miRNAs target them instead of the oncogene, which in turn leads to 
increased protein levels of the latter. If their sites mimic those of a tumor-
suppressor, then these lncRNAs are selectively down-regulated, leading to 
increased targeting of the tumor-suppressor in cancer cells [157, 158]. 
2. They interfere with the degradation of the mRNAs, either by interacting with 
the mRNA in a way that blocks the recognition sites of a miRNA, or by 
interacting with the proteins that are responsible for the degradation of the 
mRNA. Finally, in some cases lncRNAs are able to form hairpins, that can be 
identified and cleaved by Drosha, thus leading to the formation of a miRNA 
[159-161]. 
3. They may affect the translation of an mRNA, either by interacting with the 
ribosome, or with the mRNA, both in a negative or positive manner, depending 
on the lncRNAs’ way of function [162]. 
4. They may produce functional small peptides, that are involved in a variety of 
biological processes [163]. 
Both in the cytoplasm and the nucleus, various cases of lncRNAs that enable 
interactions between different proteins have been found, especially in regard to 
molecular chaperones, mostly in a complex-stabilizing function (the roles of lncRNAs 
are summarized in Figure 11) [164].  
Two examples of SNPs that alter the function of lncRNAs in cancer are the SNPs 
rs6434568(C>A) and rs16834898(A>C) in PCGEM1, which have been associated with 
increased risk for prostate cancer appearance by enhancing the lncRNAs’ ability to 
suppress the effect of drugs like doxorubicin, inhibiting cancer cell apoptosis [165]. An 
example of a SNP with a protective role, is SNP rs1317082(T>C) at exon 1 of CCSlnc362, 
which acts by creating a target site at the lncRNA for miR-4658, thus nullifying the 
lncRNA’s ability to promote cellular proliferation and inhibition of apoptosis [166]. 
Investigating SNP-SNP interactions that lie within different lncRNAs can also be crucial, 
as it has been shown that interactions between 3 SNPs (rs17729428 TG+GG>TT, 
rs7958904 G>C and rs1899663 T>G) in the HOTAIR locus with the rs1859168(A>C) in 
the HOTTIP locus increase  gastric cancer susceptibility  through combinatorial miRNA 
target gain and loss [167]. Alterations in lncRNA expression levels have also been 
heavily linked with presence of CNVs, as 147 lncRNAs (such as FENDRR, which 
promotes the PRC2 mediated promoter methylation) have been shown to be 
downregulated in presence of CNVs in hepatocellular carcinoma [168]. 
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Figure 11: Roles of lncRNAs in the nucleus and the cytoplasm. In the nucleus lncRNAs are involved in 
chromatin epigenetic modifications, chromatin looping, transcription regulation and transcript 
splicing. In the cytoplasm, lncRNAs are involved in the translation procedure, and have multiple roles 
in miRNA-regulated mRNA degradation process. Both in the nucleus and the cytoplasm lncRNAs 
regulate protein interactions and trafficking of TFs. 
Thus, studying lncRNA regulatory function and expression profile together with their 
associated variants can be beneficial for finding new diagnostic tools and/or 
therapeutic targets with high specificity and sensitivity for various types of cancer, 
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2. Aim of the study 
 
This study focuses on the experimental validation of enhancer activity   through the 
regulation  neighboring lncRNA expression in gastric cancer. Apart from cancer 
specificity, these enhancer elements should be susceptible to cancer specific variation, 
due to the occurrence of somatic or germline SNPs. As a proof of concept during this 
study, we will create the necessary tools to gain insights on the regulatory effects of 
SNPs that reside within a putative enhancer element in the genomic locus of RECUR1, 
a lncRNA with putative oncogenic role in gastric cancer that was previously identified 
in our laboratory. This is achieved through the utilization of bioinformatic and 
experimental data, according to the following experimental pipeline :  
1. First validate that the identified regulatory sequence act as an enhancer 
element of RECUR1 ex vivo, 
2. Subsequently isolate the enhancer sequence from the genome of gastric 
cancer cells   
3. Thirdly, create the necessary experimental tools for the functional 
characterization of the enhancer element along with its embedded genetic 
lesion , in order to study their regulatory capacity on RECUR1 transcription. 
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3. Materials and Methods 
 3.1 Cell culture and CRISPR activation system application 
All sgRNAs were cloned in pLVU6 lentiviral vector (process shown in Cloning sector) 
and were used to create lentiviruses in modified HEK cells. The produced viruses were 
used to transfect gastric adenocarcinoma cell lines with a stable integration of dCas9 
which was created in the lab (AGDC16). 
3.2 RNA extraction and DNase treatment 
Each RNA extraction was performed by using Trizol reagent (Tri reagent, MCA) with 
added chloroform for organic-aquatic phase separation and acquirement of the 
aquatic phase which contains the RNA part of the sample. Then, two subsequent 
isopropanol precipitation in presence of added glycogen and ethanol washing steps 
were performed to wash up the sample, and after removing the entire quantity of 
ethanol (pipetting & air drying), the RNA pellets were diluted in RNase free H2O. All 
processes were performed in ice and the centrifugations in 4 ˚C (at maximum RPM), 
to avoid RNA degradation. Removal of residual DNA happens with a DNase reaction 
using DNaseI (ThermoFisher Scientific cat. #89836), according to the reaction protocol 
seen in Table1.  
Reagent Quantity (30 μl reaction) Duration 1h 
10X DNaseI Buffer 3μl Temperature  
37˚C 
DNaseΙ (1U/μl) 1μl 
RNase-out 0,5μl 
WFI 0,5 μΙ 
RNA sample 25μl (<10μg RNA) 
Table 1: DNaseI reaction 
Following the DNaseI reaction, a phenol-chloroform-isoamyl alcohol phase separation is 
performed, and collection of the aquatic phase, in order to proceed with ethanol precipitation 
(100% ethanol) and an ethanol washing step (70% ethanol). After complete ethanol removal, 
dilution of the RNA pellet is performed with RNase-free water.  
3.3 cDNA synthesis and qPCR 
For the cDNA synthesis protocol, the reaction is performed following the instructions 
of the provider (Invitrogen Catalog number: 28025013) The cDNA synthesis reaction 
took place at 37 ˚C for 2 hours. For the qPCR reaction, the KAPA SYBRfast universal 
qPCR reaction buffer is used according to manufacturer instructions(Sigma Aldrich 
SKU KK4601). All qPCR reactions were run in Bio-Rad CFX Connect Real-Time PCR 
machine and analyzed using Bio-Rad CFX manager and MS Excel. 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly




In order to clone the enhancer sequence, a PCR standardization reaction using the Taq 
DNA polymerase from KAPA Biosystems was performed, with the following protocol: 
Reagent Enhancer (μL) 
Sample AGS gDNA 3,3 
10X Reaction Buffer 5 
dNTPs 1 
Primer RECUR1 Enh F1R1 2 
Taq DNA polymerase 0,3 
WFI 40,7 
Vfinal 50 
Step Duration Temperature (oC) 
Initial Denaturation 3 min 95 
Denaturation 30 sec 95 
Annealing 20 sec 58 
Extension 45 sec 72 
Repeats 35 
 
Final extension 5 min 72 
Hold Infinite 12 
Table 2: PCR protocol for parameter standardization. 
The product of the PCR reaction was run in an agarose gel (1% w/v agarose), in 
presence of EtBr for the imaging. The size of the expected amplicon is 696bp. 
Following standardization of the parameters required for obtaining the enhancer, a 
PCR using the Q5 High-Fidelity DNA polymerase is used, following the instructions 
provided by the company (New England Biolabs Catalog #M0491S -Table 3).  
Reagent Enhancer (μL) 
Sample AGS gDNA 3,3 
Buffer Q5 (5X) 10 
dNTPs 1 
Primer RECUR1 Enh F1R1 2 
Q5 polymerase 0,3 
WFI 33,4 
Vfinal 50 
Step Duration Temperature (oC) 
Initial Denaturation 2 min 98 
Denaturation 30 sec 98 
Annealing 20 sec 58 
Extension 45 sec 72 
Repeats 39 
 
Final extension 2 min 72 
Hold Infinite 12 
Table 3: PCR protocol using the Q5 DNA polymerase. 
Following the PCR reaction using the Q5 DNA polymerase, PCR clean-up was 
performed according to manufacture protocol (kit from Macherey-Nagel). 
Subsequently the PCR product was subjected to a PNK reaction. In parallel, the cloning 
vector was cleaved using EcoRV (Enzyquest) for 5 hours at 37 ˚C, in order to create the 
blunt ends for the cloning. Following vector digestion, a clean-up step was used to 
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remove the restrictive endonuclease, followed by dephosphorylation of the digested 
vector using CIP (Calf Intestinal alkaline Phosphatase from New England Biolabs 
Catalog # M0290 ) prior to ligation. For the ligation, the T4 DNA ligase (New England 
Biolabs Catalog #M0202S) was used, with a vector to insert ratio of 1:3. All reactions 
were performed according to the instructions of the providing company.  
The ligation product was used for transforming E. coli DH5α chemically competent 
cells. Single colonies were chosen for liquid cultivation (3ml, O/N cultures, 37˚C) and 
subsequent plasmid isolation by alkaline lysis to scan for positive colonies, alongside 
with insertion orientation. Proper insert cloning was verified by PCR using Taq DNA 
polymerase (Table 4), and the orientation of insertion by digestion using BsaI and 
HindIII-HF (New England Biolabs Catalog  #R0535 & # R3104S -Table 5).  
Reagents Quantity (μL) 
Plasmid (10ng/μl) 1 
10X Buffer  3 
dNTPs 1 
Primer RECUR1 Enh F1R1 2 
Taq DNA polymerase 0,3 
WFI 22,7 
Vfinal 30 
Step Duration Temperature (oC) 
Initial Denaturation 3 min 95 
Denaturation 10 sec 95 
Annealing 20 sec 58 
Extension 45 sec 72 
Repeats 30   
Final extension 5 min 72 
Hold Infinite  12 
Table 4: Diagnostic PCR protocol for insertion verification. 
Reagents Quantity (μl) 
Buffer 5 
BsaI (20U/μl) 1,5 




Table 5: Diagnostic digestion protocol for insertion orientation using BsaI/HindIII. 
3.5 Genotyping of the SNP allele – dCAPS 
To genotype the SNP in the cloned enhancer sequence, a dCAPS approach was 
selected alongside with SphI digestion. The conditions of the PCR reaction appear in 
Table 6, while the digestion reaction with SphI (Enzyquest cat. #RE038S) appears in 
Table 7. 
Reagents Quantity (μL) 
Institutional Repository - Library & Information Centre - University of Thessaly
30/12/2021 10:06:04 EET - 137.108.70.14
25 
 
Plasmid (10ng/μl) 1 
10X Buffer  5 
dNTPs 1 
Primer RECUR1 Enhancer dCAPS F1R1 2 
Taq DNA polymerase 0,3 
WFI 40,7 
Vfinal 50 
Step Duration Temperature (oC) 
Initial Denaturation 5 min 95 
Denaturation 30 sec 95 
Annealing 20 sec 60 
Extension 30 sec 72 
Repeats 45   
Final extension 2 min 72 
Hold Infinite  12 
Table 6: Diagnostic PCR protocol for dCAPS 
Reagents Quantity 
Buffer 5 




Table 7: Digestion protocol for dCAPS. 
3.6 Site Directed Mutagenesis 
Following SNP genotyping, the next step was to create an enhancer carrying the other 
allele (Mutant allele). To achieve this, a Site Directed Mutagenesis (SDM) protocol was 
performed. For this, 2 SDM PCR reactions (PCR 1 & PCR 2), each with an 40nt SDM 
primer with complementary sequence to each other were performed. The conditions 
of the reaction appear at Table 8.  
Reagents Quantity (μL) 
Plasmid (10ng/μl) 1 
5X Buffer  10 
dNTPs 1 
Primers (F1-SDM_R or SDM_F-R1) 1,5 for each primer 
Q5 DNA polymerase 0,25 
WFI 34,75 
Vfinal 50 
Step Duration Temperature (oC) 
Initial Denaturation 3 min 98 
Denaturation 10 sec 98 
Annealing 10 sec 58 (PCR 1) / 60 (PCR 2)  
Extension 20 sec 72 
Repeats 20 (PCR 1) / 15 (PCR 2)   
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Final extension 2 min 72 
Hold Infinite  12 
Table 8: Conditions for the SDM PCRs 1 & 2 for creating the mutated allele. 
After successfully obtaining the first 2 PCRs of the protocol, the 2 PCR products can be 
used as a template, in order to recreate the complete enhancer sequence carrying the 
induced mutation via a third PCR reaction using the primers for the full-length cloning 
of the enhancer (Table 9) 
Reagents Quantity (μL) 
PCR_1 and PCR_2 products(diluted samples 
for equal molecular analogy) 
1 each 
5X Buffer 10 
dNTPs 1 
Primers (Enhancer full length cloning F1R1) 1,5 for each primer 
Q5 DNA polymerase 0,25 
WFI 33,75 
Vfinal 50 
Step Duration Temperature (oC) 
Initial Denaturation 3 min 98 
Denaturation 10 sec 98 
Annealing 10 sec 58  
Extension 45 sec 72 
Repeats 25 
 
Final extension 2 min 72 
Hold Infinite 12 
Table 9: Conditions for the third PCR of the SDM reaction protocol for full length enhancer obtainment. 
SDM was verified again with dCAPS (described above) and the mutated enhancer 
sequence was ligated to the same vector in both orientations (described above). Final 
cloning products were verified base to base with Sanger sequencing performed with 
CeMIA.   
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4.1 Bioinformatic analysis 
The bioinformatic analysis (performed previously in the lab) showed two SNPs in the 
vicinity of the RECUR1 locus (REgulatory Cancer mUtation lncRNA 1). RECUR1 
transcribes a lncRNA with increased expression levels in patients with gastric cancer 
that was identified and initially characterized previously in our laboratory. The two 
SNPs reside i) upstream of the RECUR1 TSS and ii) within a nearby candidate enhancer 
element. Characterization of the regulatory role of the enhancer in RECUR1 expression 
alongside with the functional role of the embedded SNP may provide insights for 
gastric cancer predisposition alongside with applications in personalized diagnosis and 
therapy. This will be achieved through experimental validation via CRISPRa of the 
enhancer. Then, the enhancer sequence will be obtained by PCR and subsequently 
cloned to the appropriate vector.  The presence of the allele will be verified by 
genotyping.  
4.2 CRISPRa targeting the enhancer 
Prior to downstream experiments, the regulatory role of the putative enhancer must 
be proven through correlation with increased RECUR1 expression. Verification of the 
regulatory capacity of the enhancer was performed with CRISPRa targeting the 
enhancer sequence. The RECUR1 promoter sequence was also included as a control. 
The first experiment of CRISPRa in AGdC16 cells (Fig. 1) was not successful in 
overexpressing RECUR1, so a second experiment (Fig. 2) was performed using HdC1 
(HEK epithelial cells expressing dCas9 clone 1), LdC10 (LS174 cells expressing dCas9 


















Normalized RECUR1 expression in AGdC16 cells
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Figure 1: RECUR1 expression levels in AGdC16 cells. Overexpression of RECUR1 was not successful in the 
case of the sgRNAs targeting the enhancer in comparison to the expression levels achieved by targeting 
the promoter. All results were depicted as fold change in comparison to the control (empty vector). 
 
Figure 2: RECUR1 expression in HdC1, LdC10 and AGdC16 cells. Targeting of the enhancer using the 
sgRNA2 was successful in overexpressing RECUR1 in HdC1 and LdC10 cell lines, thus proving that the 
enhancer can regulate RECUR1. The sgRNA targeting the promoter showed increased expression of 
RECUR1 in all cell lines, while simultaneous targeting of the promoter and the enhancer managed to 
overexpress RECUR1, albeit in a smaller extent than single targeting of the promoter. All results for each 
cell line were depicted as fold change in comparison to the control (pLVU6).The diagram does not 
contain error bars, as it is based on one biological replicate due to time restrictions. 
As the two enhancer-targeting sgRNAs were unable to overexpress the lncRNA in a 
greater extent, additional sgRNAs were designed and successfully cloned to 
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Figure 3: Diagnostic PCR indicating the successful insertion of the sgRNA3 and sgRNA4 with a sequence 
to target the enhancer regulating RECUR1. Electrophoresis performed on 1% Agarose gel. 
In the samples from the second experiment, another qPCR was performed the nearby 
protein coding genes to investigate alterations in their expression levels that could 
reflect regulation from the same enhancer element directly or indirectly by the 
lncRNA.  
According to the results obtained by this experiment (Fig.4) a clear effect in the 
expression of both nearby genes was observed upon targeting of the RECUR1 
promoter. On the other hand, the enhancer showed a steady profile in regulating the 
mRNA target 2 alongside with a tissue-specific potential for regulating mRNA target 1 
depending on the cellular context.  
 
Figure 4: qPCR showing alterations in mRNA1 and mRNA2 levels. All results for each cell line were 
depicted as fold change in comparison to the control (pLVU6). In all samples, increased levels of mRNA2 
were observed, for all target sites. mRNA1 expression alterations are target- and cell line-specific, as 
increase appears in all CRISPRa cases that are targeting the RECUR1 promoter.  On the other hand, 
targeting of the enhancer results in decrease in HdC1 epithelial cells, yet increase in LdC10 and AGdC16 
gastrointestinal cells. Simultaneous targeting of the promoter and the enhancer led to increased levels 
of mRNA1 in HdC1 and LdC10, but reduced expression levels in AGdC16. 
 
4.3 Cloning of the enhancer 
After proving the regulatory potential of the enhancer element, the next step was to 
successfully obtain its sequence from genomic DNA (Fig. 5). 
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Figure 5: Electrophoresis of the PCR used to obtain the full-length Promoter and Enhancer of RECUR1. 
Expected amplicon for the promoter → 1000bp, expected amplicon for the enhancer 696 bp. 
Electrophoresis performed on 1% Agarose gel. 
Following ligation to the vector and transformation to bacterial cells, single colonies 
were picked to extract the plasmids carrying the enhancer and promoter sequences 
(PCR result in Fig. 6) in both insertion orientations (Fig. 7). The insertion orientation is 
required to verify whether each element acts indeed as a promoter (unidirectional 
function) and enhancer (bidirectional function). 
 
Figure 6: Diagnostic PCR proving cloning of the promoter and the enhancer sequences. Expected 
amplicon for the promoter → 1000bp, expected amplicon for the enhancer 696 bp. Electrophoresis 
performed on 1% Agarose gel. 
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Figure 7: Digestion to clarify orientation of the promoter insertion. The expected products are: 5’-3’→ 
230bp, 3’-5’→ 760bp. Electrophoresis performed on 1% Agarose gel. 
As seen in Figure 6, the 1st and 4th clones of the promoter and all tested clones of the 
enhancer carried the insert. Luckily, the 1st clone of the promoter had the 5’-3’ 
insertion orientation while the 4th clone of the promoter was inserted with the 3’-5’ 
orientation (Figure 7). For the enhancer all initial positive clones had the same 
orientation, therefore additional colonies were picked and checked for the insertion 
orientation (Fig. 8). 
 
Figure 8: Digestion to clarify orientation of the enhancer. The expected products are: 5’-3’→ 497, 3’-5’ 
→ 339. Green symbolizes the selected positive clones. Electrophoresis performed on 1% Agarose gel. 
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The 1st clone from the first batch of clones picked (which contained the 5’-3’ insertion 
orientation), and the 1st clone from the 4th batch (which contained the 3’-5’ insertion 
orientation) were chosen for genotyping and subsequent Sanger sequencing (see 
below).  
4.4 Genotyping and Site-Directed Mutagenesis 
In order to validate the SNP allele in all cloned enhancer sequences, a dCAPS was 
performed. Digestion with SphI showed that both enhancer orientation clones 
selected in the previous step (see above, Fig 8) carried the wild-type allele predicted 
to associate with reduced gastric cancer onset (Fig. 9).  
 
Figure 9: Genotyping of the cloned enhancer sequence with the 5’-3’and 3’-5’ insertion orientation. 
Uncut→ the sample received after PCR and PCR clean-up and was not subjected to digestion. Cut→ The 
digested PCR product. In this case, the enhancer carries the Wild-Type allele, which disrupts the 
recognition site for the restrictive endonuclease. PCR/Enhancer carrying the WT allele → 334 bp band. 
Electrophoresis performed on 2% Agarose gel. 
Following this result, a Site Directed Mutagenesis was performed for creating 
constructs harboring the alternative mutant allele according to [171]. PCR1 for the 
protocol was unsuccessful at the first attempt but was successfully obtained after 
some fine-tuning of the PCR conditions in the second attempt. PCR2 was successful on 
the first attempt (Fig. 10). The subsequent 3rd reaction for the SDM was duplicated to 
maximize the quantity of the final PCR product prior to ligation. The result of the 
successful attempt appears at Figure 11. 
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Figure 10: 1st (F1/SDM_R primers) and 2nd (SDM_F/R1 primers) PCR reactions for the SDM protocol. Red 
colorization→ Unsuccessful first attempt at 1st PCR. Green colorization → Successful amplification of 
the PCR products for each PCR reaction. Electrophoresis performed on 1% Agarose gel. 
 
Figure 11: Successful recovery of the full-length enhancer fragment that carries the mutated allele. The 
expected band appears at 696 bp. The reaction was duplicated to have enough quantity prior to ligation. 
Electrophoresis performed on 1% Agarose gel. 
4.5 Cloning of the SDM products 
A similar cloning approach was used to generate the constructs carrying the mutated 
allele as with the WT enhancer sequence. Following successful recovery of the 
mutated full-length enhancer (Fig. 11), 10 clones were picked to scan for positive 
insertion, as well as the insertion orientation, using a diagnostic double digestion with 
BsaI/HindIII (Fig. 12). After successfully obtaining the insert both in the 5’-3’ (2nd and 
8th clones) and 3’-5’ (4th and 9th clones) insertion orientations, one of each orientation 
(2nd and 4th clone) were selected to proceed to genotyping and sequencing. 
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Figure 12: Diagnostic digestion using BsaI/HindIII to verify presence and insertion orientation of the 
insert. Red coloration → Negative clones for the insertion. Green coloration → Positive clones for the 
insertion. Expected bands: 5’-3’ → 497 bp, 3’-5’→339 bp. The 2nd and 8th samples carried the insert with 
5’-3’ insertion orientation and 4th and 9th clones carried the 3’-5’ insertion orientation. The 2nd and 4th 
clones were selected for subsequent experiments. Electrophoresis performed on 1% Agarose gel. 
4.6 Genotyping of the clones carrying the SDM products 
Using the selected enhancer clones from the previous step, the next goal was to verify 
whether the SDM conversion was successful, and the cloned enhancer sequence 
indeed carried the mutated allele for the SNP of focus. To do that, a dCAPS approach 
[172] was performed (same strategy as in section 4.4) using SphI, which only cleaves 
in presence of the mutated allele. Indeed, the SDM mutagenesis was successful, as 
the enzyme was able to cleave (partial digestion due to excess amount of PCR product 
in the reaction) the enhancer sequence at the site of the allele, generating a 294bp 
and a 40 bp band (Fig. 13). 
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Figure 13: Genotyping of the enhancer sequence carried in the two plasmids with the 5’-3’and 3’-5’ 
insertion orientation. The expected bands are for the PCR/Enhancer carrying the WT allele → 334 bp 
band, and for the digested enhancer with the mutated allele → 294bp and 40bp band. Uncut→ the 
sample received after PCR and PCR clean-up and was not subjected to digestion. Cut→ The digested 
PCR product. The result shows that partial digestion occurred in the restriction digest reaction with SphI, 
indicating: 1) excess amount of PCR product present in the sample, that did not allow complete digestion 
and 2) the presence of the mutated allele which creates the cleaving site for SphI, thus concluding that 
the SDM conversion was successful. Electrophoresis performed on 2% Agarose gel. 
These samples that carried the mutated allele were sent for sequencing, along with 
the samples carrying the WT allele. Sequencing results proved that each individual 
clone from both experiments (clones obtained with both orientations with and 
without SDM conversion) indeed carried the respective alleles, thus verifying the 
dCAPS results (Fig. 14). Sequencing results also verified the insertion and orientation, 
as shown with restriction digest, as well as a 100% sequence match to the enhancer 
sequence compared to the human genome assembly (with the exception of the 
mutated SNP allele). Thus, those clones could now be used for a luciferase assay to 
test the regulatory capacity of the enhancer and the SNP contained within it.  
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Figure 14: Sequencing results, focused on the adjacent area of the SNP within the enhancer. The SNP 
allele in each sample appears highlighted with yellow colorization. All samples carried the expected 
allele based on the previous results. 
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SNPs are major players in disease onset [173]. Their presence has been correlated with 
deregulated protein function, alterations in ncRNA mechanism and can drastically 
affect the function of DNA regulatory elements [174-176]. In the presence of coding 
SNPS, protein function can be affected either through altered amino-acid sequence or 
through alternative splicing (intron retention, exon exclusion) [177]. On a regulatory 
level, altered protein levels may occur due to SNP presence within the transcripts’ 
UTRs, the miRNAs that target them, or by alterations in the proteins’ non-transcribed 
regulatory machinery [178]. SNPs might alter the binding affinity of transcription 
factors at regulatory elements [179]. Additionally, studies have shown that presence 
of SNPs affect the function of ncRNAs, either by affecting their maturation process or 
their secondary structure[180].  
Focusing on the effect of SNPs in enhancer regions, many studies have shown their 
effect in deregulating both coding and non-coding RNA expression. Such an example 
is the SNP rs1892901, a disease-related SNP detected in high occurrence in Chinese 
populations. This SNP is correlated with multiple forms of cancers, most prominently, 
gastric. It is situated near an enhancer element regulating FOSL1 (FOS-like antigen 1), 
a proto-oncogene with pivotal role in cell proliferation, differentiation, and 
metastasis. This occurs as FOSL1 has been identified as a deregulator of PI3K/Akt and 
p53 pathways in gastric cancer cells [181]. Analyses showed that rs1892901 can be 
part of transcription factor binding sites, and affect the binding affinity of multiple 
transcription factors, such as EGR1, CHD, EP300, FOS, JUN, FOSL1, and FOSL2 [182]. 
All these transcription factors have a well-established role in gastric cancer 
appearance [183-186]. 
Two SNPs with a high risk for colorectal cancer are rs10505477 and rs10411210 [187]. 
rs10505477, in particular, has also been corelated with increased risk for intestinal 
type of gastric cancer, affecting the patients’ survival and treatment response [188]. 
These SNPs lie within super-enhancers bound by CDX2 and HNF4α, two oncogenic 
transcription factors known to regulate colonic development [189, 190]. The risk 
alleles of both SNPs are correlated with increased levels of H3K27ac at their respective 
super-enhancers in comparison to normal alleles, thus proving a correlation between 
histone modifications and DNA sequence [191].  
HOTAIR is one of the most well-characterized lncRNAs, and its role is highlighted in 
gastric cancer, as well as other cancer forms, acting as a predictor of the patients’ 
survival [192-194]. Mechanistically, it interacts with Polycomb Repressive Complex 2 
(PRC2) and lysine-specific demethylase 1 (LSD1), targeting them to certain genomic 
loci. As a result, multiple tumor-suppressor genes, like JAM2, PCDH10 and PCDHB5 are 
downregulated, while several oncogenes like SNAIL are overexpressed [195]. Multiple 
SNPs have been found regulating the expression of HOTAIR in gastric cancer (along 
with many other forms). rs920778 lies within an intronic enhancer of HOTAIR, has 
been a heavily disputed SNP correlated with increased expression of HOTAIR in gastric 
cancer and esophageal squamous cell carcinoma [196, 197].  On the other hand, the 
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high prostate and lung cancer risk SNP rs1899663 is located in a putative regulatory 
element within HOTAIR, and alters the binding affinity of PAX-4, SPZ1, and ZFP281 
through altering the chromatin accessibility in the region [198].  
Another lncRNA regulated by a SNP lying within an enhancer element, it PCAT1 
(Prostate Cancer Associated Transcript 1). PCAT1 is directly involved in prostate cancer 
cell proliferation and castration resistance, while it has been correlated with gastric 
cancer appearance. The high-risk T allele of the SNP rs7463708 (T>G) increases the 
binding affinity of ONECUT transcription factor family members (like HNF4 and HNF6) 
and AR (androgen receptor). In turn, the PCAT1 transcript interacts with LSD1 and AR, 
targeting them to enhancers regulating GNMT and DHCR24, two genes with 
established role in prostate cancer progression [199-203]. In gastric cancer, in 
particular, PCAT1 upregulates the expression of CDKN1A, leading to increased cell 
proliferation, migration, and invasion [204].   
A novel enhancer studied during this thesis, is an enhancer regulating RECUR1. The in-
silico analysis showed the SNP lying within this enhancer sequence has a positive 
correlation with gastric cancer appearance. Its role in enhancer function is yet to be 
found, as well as the way it may affect the binding of KLF5 to the enhancer element. 
The next step of the analysis is to verify how the mutated dominant allele may affect 
the functionality of the enhancer in an episomal assay in cellulo. But, since this is an 
episomal assay that studies the functionality of the enhancer away of its natural 
habitat within its specific genomic locus, another assay needs to be performed, which 
would alter the SNP allele on genomic DNA level. Such an approach is a CRISPR editing 
with a homologous recombination approach targeted at the site of the SNP. This 
would require the conduction of an experiment monitoring RECUR1 expression both 
in cells homozygous for the recessive allele, as well as cells homozygous for the 
dominant-cancer related allele. This experiment would allow the characterization of 
the SNP as a driver or passenger variant. Depending on the result (both from the 
episomal and the genome editing assays), multiple experiments can be performed to 
test transcription factor binding to the enhancer and local chromatin architecture. A 
chromatin immunoprecipitation using antibodies for KLF5 followed by qPCR (ChIP-
qPCR protocol) can be used with chromatin from cells carrying each allele in a 
homozygous state. This experiment would provide information about the binding 
ability of KLF5 in presence of each allele. Additional experiments may also focus on 
detection of other transcription factors that may also bind in this enhancer, but this 
would require extra analysis of metagenomic data coupled with immunoprecipitation 
and Mass Spectrometry for their detection. Another experiment that can be 
performed is a chromosome confirmation capture (3C), possibly coupled with qPCR 
[205]. This protocol would correlate the genome architecture through loop formation 
in the genome locus with the presence of each allele. This would lead to a complete 
mechanistical characterization of the SNP and its effect on enhancer activity. 
Ultimately, if this SNP indeed proves to have an allele-specific correlation with 
increased risk for gastric cancer appearance, it would be vastly beneficial for a 
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prognostic and diagnostic tool development. More specifically, such tools would 
provide an easy and cost-efficient method to detect an individual’s probability to 
succumb to the disease [206]. This allows a better monitoring of each person within a 
population even at a young age, prior to appearance of the disease to receive 
precaution measures, or the disease will be detected at an early stage, in which it is 
still curable. Depending on the results from further analyses focused on the enhancer 
function, along with the role of the lncRNA, it may enable their therapeutic targeting. 
This might be achieved either through pharmaceutical targeting focused at the 
lncRNA, or through genome editing focusing on the enhancer or the lncRNA[207]. 
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